Current antiretroviral combination therapy is extremely effective at suppressing HIV-1 viremia below to the limit of detection of standard clinical assays, however it is unable to fully eradicate HIV-1. As a consequence, once treatment is stopped, HIV-1 replication can rapidly rebound from the latent reservoir, and typically reaches pre-treatment levels of HIV-1 replication within a short period of time. Thus, the understanding of mechanisms contributing to HIV-1 persistence despite ART, and the development of therapeutic strategies that target persistent virus, represent one of the highest priorities in current HIV-1 research. In this application, we hypothesize that in samples from long- term treated individuals, infected long-lived CD4 T cells will preferentially express HIV RNA-TAR, which will confer to the cells a survival advantage. Thus, here we propose to deeply characterize single cells exclusively expressing HIV RNA-TAR in CD4 T subsets from ART-treated patients. In addition, HIV integration sites sequencing will be used to determine the long-term persistence and the clonal expansion capabilities of cells expressing HIV RNA-TAR during prolonged ART. If successful, these investigations may lead to the identification of the exclusive signatures of latently infected cells in vivo, re-directing current efforts in design clinical straegies aimed at cure HIV, thus addressing one of the highest-priority issues in current HIV-1 research.

Public Health Relevance

Identifying the mechanisms by which HIV is able to persist for prolonged periods of time in patients under antiretroviral therapy is crucial for the development of new strategies targeting the latent reservoir. In here, we propose to deeply characterize resting CD4 T cells from ART-treated patients expressing the TAR RNA element in a effort to identify exclusive signatures of latently infected cells in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI118411-01
Application #
8922392
Study Section
Special Emphasis Panel (ZRG1-AARR-E (56))
Program Officer
Stansell, Elizabeth H
Project Start
2015-08-01
Project End
2017-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
1
Fiscal Year
2015
Total Cost
$162,000
Indirect Cost
$12,000
Name
Fdn Institute/Research/Vall D'Hebron Hos
Department
Type
DUNS #
474373995
City
Barcelona
State
Country
Spain
Zip Code
08035
Martinez-Picado, Javier; Zurakowski, Ryan; Buzón, María José et al. (2018) Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence. Retrovirology 15:15
García, Marcial; Buzón, María J; Benito, José M et al. (2018) Peering into the HIV reservoir. Rev Med Virol 28:e1981
Abdel-Mohsen, Mohamed; Kuri-Cervantes, Leticia; Grau-Exposito, Judith et al. (2018) CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med 10:
Vibholm, Line; Schleimann, Mariane H; Højen, Jesper F et al. (2017) Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. Clin Infect Dis 64:1686-1695
Grau-Expósito, Judith; Serra-Peinado, Carla; Miguel, Lucia et al. (2017) A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients. MBio 8:
Barton, Kirston; Hiener, Bonnie; Winckelmann, Anni et al. (2016) Broad activation of latent HIV-1 in vivo. Nat Commun 7:12731